Please assess the completion status of the following clinical trial:

Trial Title: Study of Efficacy and Safety in Polycythemia Vera Subjects Who Are Resistant to or Intolerant of Hydroxyurea: JAK Inhibitor INC424 (INCB018424) Tablets Versus Best Available Care: (The RESPONSE Trial)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Participants diagnosed with PV for at least 24 weeks prior to screening according to the 2008 World Health Organization criteria~* Participants resistant to or intolerant of hydroxyurea~* Participants with a phlebotomy requirement~* Participants with splenomegaly (palpable or non-palpable) and a spleen volume, as measured by MRI (or CT in applicable participants ), of greater than or equal to 450 cubic centimeters~* Participants with an Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1 or 2~Exclusion Criteria:~* Women who are pregnant or nursing~* Participants with inadequate liver or renal function~* Participants with significant bacterial, fungal, parasitic, or viral infection requiring treatment~* Participants with an active malignancy within the past 5 years, excluding specific skin cancers~* Participants with known active hepatitis or HIV positivity~* Participants who have previously received treatment with a JAK inhibitor~* Participants being treated with any investigational agent

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- ruxolitinib tablets (Type: EXPERIMENTAL): Starting dose of 10 mg BID with individualized dose titration ranging from 5 mg once a day (QD) to 25 mg BID based on safety and efficacy
- Best Available Therapy (Type: OTHER): Best Available Therapy (BAT) will be selected by the Investigator for each participant. BAT may not include experimental agents (i.e. those not approved for the treatment of any indication) as well as a limited number of other selected drugs in accordance with the protocol-defined requirements.

Based on this trial design, predict the completion outcome and termination type (if applicable).